Furthermore, PD-L1 overexpression in tumor cells inhibits T cell-mediated anti-tumor immunity via PD-1 on tumor infiltrating lymphocytes, which protects tumor cells from cytotoxic lysis and ultimately influences patients’ clinical outcomes [35]. This evidence concerns the gene CD274 and neoplasm.